Product How it works Pricing Blog FAQ About Contact
CytomX Therapeutics

CytomX Therapeutics (NASDAQ: CTMX) net income

CytomX Therapeutics reported a net loss of $17.4m for fiscal 2025; in fiscal 2024 it reported a net profit of $31.9m.

CytomX Therapeutics's best year of the last 10 was fiscal 2024. It reported a loss in 9 of those 10 years.

Net income, in millions of US dollars-58.92016-43.12017-84.62018-132.82019-64.82020-115.92021-99.32022-0.6202331.92024-17.42025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet margin
2025−$17.4m−154.5%−22.8%
2024$31.9m—23.1%
2023−$0.6m—−0.6%
2022−$99.3m—−186.8%
2021−$115.9m—−310.5%
2020−$64.8m—−94.7%
2019−$132.8m—−493.7%
2018−$84.6m—−142.2%
2017−$43.1m—−60.2%
2016−$58.9m—−391.5%

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

CytomX Therapeutics net income compared with its sector

By net income for its latest fiscal year, CytomX Therapeutics ranks 203rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of CytomX Therapeutics, −22.8%.

RankCompanyNet incomeNet margin
201stPalisade Bio−$16.8m—
202ndAlpha Teknova−$17.3m−42.6%
203rdCytomX Therapeutics−$17.4m−22.8%
204thOvid Therapeutics−$17.4m−240.1%
205thRadNet−$18.7m−0.9%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of CytomX Therapeutics

How much did CytomX Therapeutics earn in fiscal 2025?
CytomX Therapeutics reported a net loss of $17.4m for fiscal 2025. In fiscal 2024 it reported a net profit of $31.9m.
What was the most profitable year for CytomX Therapeutics?
Of its last 10 fiscal years, fiscal 2024, with $31.9m.
Where does CytomX Therapeutics rank in its sector by net income?
It ranks 203rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for CytomX Therapeutics come from?
From the annual report (Form 10-K) that CytomX Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that CytomX Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on CytomX Therapeutics: the CytomX Therapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.